OBJECT: Approximately 10% of cerebrospinal fluid (CSF) shunt operations are associated with infection and require removal or externalization of the shunt, in-hospital treatment with antibiotic agents, and insertion of a new shunt. In a previous survey, the authors identified substantial variation in the duration of antibiotic therapy as well as the duration of hospital stay. The present multicenter pilot study was undertaken to evaluate current strategies in the treatment of shunt infection. METHODS: Patients were enrolled in the study if they had a successful treatment of a CSF shunt infection proved by culture of a CSF specimen. Details of their care and the incidence of culture-proved reinfection were recorded. Seventy patients from 10 centers were followed up for 1 year after their CSF shunt infection. The initial management of the infection was shunt externalization in 17 patients, shunt removal and external ventricular drain insertion in 50, and antibiotic treatment alone in three. Reinfection occurred in 18 patients (26%). Twelve of the 18 reinfections were caused by the same organism and six were due to new organisms. The treatment time varied from 4 to 47 days, with a mean of 17.4 days for those who later experienced a reinfection compared with 16.2 days for those who did not. The most common organism (Staphylococcus epidermidis, 34 patients) was associated with a reinfection rate of 29% and a mean treatment time of 12.8 days for those who suffered reinfection and 12.5 days for those who did not. CONCLUSIONS: Reinfection after treatment of a CSF shunt infection is alarmingly common. According to the data available, the incidence of reinfection does not appear to be related to the duration of antibiotic therapy.
OBJECT: Approximately 10% of cerebrospinal fluid (CSF) shunt operations are associated with infection and require removal or externalization of the shunt, in-hospital treatment with antibiotic agents, and insertion of a new shunt. In a previous survey, the authors identified substantial variation in the duration of antibiotic therapy as well as the duration of hospital stay. The present multicenter pilot study was undertaken to evaluate current strategies in the treatment of shunt infection. METHODS:Patients were enrolled in the study if they had a successful treatment of a CSF shunt infection proved by culture of a CSF specimen. Details of their care and the incidence of culture-proved reinfection were recorded. Seventy patients from 10 centers were followed up for 1 year after their CSF shunt infection. The initial management of the infection was shunt externalization in 17 patients, shunt removal and external ventricular drain insertion in 50, and antibiotic treatment alone in three. Reinfection occurred in 18 patients (26%). Twelve of the 18 reinfections were caused by the same organism and six were due to new organisms. The treatment time varied from 4 to 47 days, with a mean of 17.4 days for those who later experienced a reinfection compared with 16.2 days for those who did not. The most common organism (Staphylococcus epidermidis, 34 patients) was associated with a reinfection rate of 29% and a mean treatment time of 12.8 days for those who suffered reinfection and 12.5 days for those who did not. CONCLUSIONS: Reinfection after treatment of a CSF shunt infection is alarmingly common. According to the data available, the incidence of reinfection does not appear to be related to the duration of antibiotic therapy.
Authors: Scott L Parker; Frank J Attenello; Daniel M Sciubba; Giannina L Garces-Ambrossi; Edward Ahn; Jon Weingart; Benjamin Carson; George I Jallo Journal: Childs Nerv Syst Date: 2008-11-05 Impact factor: 1.475
Authors: Tamara D Simon; Nicole Mayer-Hamblett; Kathryn B Whitlock; Marcie Langley; John R W Kestle; Jay Riva-Cambrin; Margaret Rosenfeld; Emily A Thorell Journal: J Pediatric Infect Dis Soc Date: 2013-08-26 Impact factor: 3.164
Authors: Ian K White; Kashif A Shaikh; Obed M Nyarenchi; Madan G Kundu; Joel C Boaz; Daniel H Fulkerson Journal: Childs Nerv Syst Date: 2015-02-25 Impact factor: 1.475
Authors: John R W Kestle; Jay Riva-Cambrin; John C Wellons; Abhaya V Kulkarni; William E Whitehead; Marion L Walker; W Jerry Oakes; James M Drake; Thomas G Luerssen; Tamara D Simon; Richard Holubkov Journal: J Neurosurg Pediatr Date: 2011-07 Impact factor: 2.375
Authors: Tamara D Simon; Matthew P Kronman; Kathryn B Whitlock; Nancy E Gove; Nicole Mayer-Hamblett; Samuel R Browd; D Douglas Cochrane; Richard Holubkov; Abhaya V Kulkarni; Marcie Langley; David D Limbrick; Thomas G Luerssen; W Jerry Oakes; Jay Riva-Cambrin; Curtis Rozzelle; Chevis Shannon; Mandeep Tamber; John C Wellons; William E Whitehead; John R W Kestle Journal: J Neurosurg Pediatr Date: 2018-02-02 Impact factor: 2.375
Authors: Tamara D Simon; Matthew P Kronman; Kathryn B Whitlock; Nancy Gove; Samuel R Browd; Richard Holubkov; John R W Kestle; Abhaya V Kulkarni; Marcie Langley; David D Limbrick; Thomas G Luerssen; Jerry Oakes; Jay Riva-Cambrin; Curtis Rozzelle; Chevis Shannon; Mandeep Tamber; John C Wellons; William E Whitehead; Nicole Mayer-Hamblett Journal: J Pediatr Date: 2016-09-28 Impact factor: 4.406
Authors: Joon Kee Lee; Joon Young Seok; Joon Ho Lee; Eun Hwa Choi; Ji Hoon Phi; Seung-Ki Kim; Kyu-Chang Wang; Hoan Jong Lee Journal: J Korean Med Sci Date: 2012-12-07 Impact factor: 2.153